Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 4/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924411 | 1.00 | TUBB1 (0.51) | TUBB1MMP8MMP1MMP3PTPN1 | |
| SCHEMBL4914025 | 0.92 | TUBB1 (0.53) | TUBB1MMP8MMP1MMP3SMN1; SMN2 | |
| SCHEMBL4914022 | 0.92 | TUBB1 (0.53) | TUBB1MMP8MMP1MMP3SMN1; SMN2 | |
| SCHEMBL16169530 | 0.92 | TUBB1 (0.53) | TUBB1MMP8MMP1MMP3SMN1; SMN2 | |
| SCHEMBL4378808 | 0.89 | TUBB1 (0.60) | TUBB1MMP8MMP1MMP3MMP9 | |
| SCHEMBL4371551 | 0.89 | TUBB1 (0.60) | TUBB1MMP8MMP1MMP3MMP9 | |
| SCHEMBL4371546 | 0.89 | TUBB1 (0.60) | TUBB1MMP8MMP1MMP3MMP9 | |
| SCHEMBL4378799 | 0.89 | TUBB1 (0.60) | TUBB1MMP8MMP1MMP3MMP9 | |
| SCHEMBL4372709 | 0.89 | TUBB1 (0.50) | TUBB1MMP1MMP3SMN1; SMN2CTSB | |
| SCHEMBL4372705 | 0.89 | TUBB1 (0.50) | TUBB1MMP1MMP3SMN1; SMN2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | TUBB1 588/4885MMP8 2931/4885MMP1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.